Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) has scheduled its fourth quarter and full year 2024 financial results announcement and business update for Monday, March 3, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET on the same day.

Investors and interested parties can access the webcast through the Events & Presentations page in the Investors section of Syndax's website. Alternative access is available via phone using the conference ID: Syndax4Q24, with domestic dial-in number 800-590-8290 and international dial-in number 240-690-8800.

A replay of the conference call will be available on the company's website approximately 24 hours after the event and will remain accessible for 90 days.

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax4Q24
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX4Q24.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

When will Syndax (SNDX) release Q4 and full year 2024 earnings?

Syndax Pharmaceuticals will release its Q4 and full year 2024 financial results on Monday, March 3, 2025.

What time is the SNDX Q4 2024 earnings call?

The earnings call and webcast will take place at 8:00 a.m. ET on Monday, March 3, 2025.

How can investors access SNDX's Q4 2024 earnings call?

Investors can access the call through the live webcast on Syndax's website, or by phone using domestic dial-in number 800-590-8290 or international dial-in number 240-690-8800.

How long will SNDX's Q4 2024 earnings call replay be available?

The replay will be available on Syndax's website approximately 24 hours after the conference call and will remain accessible for 90 days.